Skip to main content
Country-Specific Sites

Artificial urinary sphincter: recent developments and the way forward

Author(s):
JOURNAL
Current Opinion in Urology
YEAR
DOI
https://doi.org/10.1097/MOU.0000000000001212
View on Publisher Site

Abstract Short Summary

This narrative review highlights recent innovations in artificial urinary sphincter (AUS) devices, clinical trials, and global guidelines from 2022–2024. It discusses new AUS technologies, updated clinical evidence, and Rigicon's ContiClassic and ContiReflex devices as emerging alternatives.

Abstract

Objective:

To review recent advancements in AUS technology, high-level clinical evidence, and guideline trends, and to identify future directions in AUS development and clinical practice.

Key Findings:

Three novel AUS devices progressed to clinical trials, including UroActive and ARTUS. Rigicon’s ContiClassic and ContiReflex were evaluated with favorable safety outcomes. The SATURN study confirmed AUS efficacy in male SUI. Guideline analysis revealed inconsistent global practices, stressing the need for standardization.

Conclusion:

Recent developments in AUS devices, especially electronic models and Rigicon’s CE-marked systems, show promise for improving outcomes and addressing limitations of the competitor devices. Coordinated global guidelines and data-driven improvements are essential for future practice.

 

Clinical Relevance:

Emerging AUS technologies and robust clinical studies are reshaping the treatment landscape for stress urinary incontinence. Rigicon’s systems offer viable alternatives that support individualized care and minimize complications.

 

Keywords

artificial urinary sphincter ContiReflex stress urinary incontinence Rigicon UroActive AUS electronic sphincter postprostatectomy incontinence

This publication is available through the external link above. See the abstract for a summary of the research.

Back to Clinical Evidence